{"id":586930,"date":"2026-08-06T00:00:00","date_gmt":"2026-08-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0006-2026-biopharma-schizophrenia-landscape-forecast-disease-landscape-forecast-major-markets\/"},"modified":"2026-08-06T23:13:21","modified_gmt":"2026-08-06T23:13:21","slug":"dlsfcg0006-2026-biopharma-schizophrenia-landscape-forecast-disease-landscape-forecast-major-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0006-2026-biopharma-schizophrenia-landscape-forecast-disease-landscape-forecast-major-markets\/","title":{"rendered":"Schizophrenia &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (Major Markets)"},"content":{"rendered":"<p><span>The <\/span>schizophrenia therapy market remains highly competitive, dominated by atypical and typical antipsychotics. Ongoing generic erosion within the atypical class continues to shape psychiatrists\u2019 prescribing behaviors, even as newer oral agents\u2014such as Caplyta (Johnson &#038; Johnson Innovative Medicine) and Cobenfy (Bristol Myers Squibb)\u2014work to expand their adoption. The long-acting injectable (<abbr data-abbreviation-entity=\"6640\" title=\"long-acting injectable\">LAI<\/abbr>) segment is also in transition, marked by intensifying competition, the launch of newer <abbr data-abbreviation-entity=\"6640\" title=\"long-acting injectable\">LAI<\/abbr>s such as Abilify Asimtufii (Lundbeck\/Otsuka) and Uzedy (Teva), and the genericization of key established brands. However, recent clinical setbacks\u2014including failures of pimavanserin, roluperidone, and iclepertin\u2014underscore the continued unmet need for efficacious therapies targeting negative symptoms and cognitive impairment associated with schizophrenia (<abbr data-abbreviation-entity=\"6535\" title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>). This report evaluates the market potential of emerging late-phase therapies such as brilaroxazine (Reviva) and milsaperidone (Vanda; Teva) and provides an in-depth profile of evenamide (Newron Pharmaceuticals), a Phase 3 sodium channel blocker being developed for treatment-resistant schizophrenia.<\/p>\n<p><strong>Questions <\/strong><strong>answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the size of the schizophrenia therapy market in the major\u00a0markets?<\/li>\n<li>Which factors drive and constrain the use of newer-to-market oral and <abbr data-abbreviation-entity=\"6640\" title=\"long-acting injectable\">LAI<\/abbr>s of atypical antipsychotics? How is competition heating up in these segments?<\/li>\n<li>How will late-phase and newly launched brands alter competitive positioning and patient-share trajectories across the major markets?<\/li>\n<li>What are the areas of highest unmet need in schizophrenia treatment?<\/li>\n<li>How will patient share, branded\u2013generic dynamics, and competitive pressures shift during the 10-year forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p><strong>Geographies:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research: <\/strong><span>35 <\/span>country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Prevalence of schizophrenia by country, segmented by symptom status; diagnosed \/ drug-treated prevalence of schizophrenia by country<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2035, segmented by brands \/generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-586930","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psychiatry","biopharma-therapy-areas-schizophrenia","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/586930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=586930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}